FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2783139623> ?p ?o ?g. }

• W2783139623 abstract "The management of human epidermal growth factor receptor 2 (HER2)-positive breast cancer has changed dramatically with the introduction and widespread use of HER2-targeted therapies. There is, however, relatively limited real-world information about the effectiveness and safety of trastuzumab emtansine (T-DM1) in Hong Kong Chinese patients. We assessed the efficacy and toxicity profiles among local patients with HER2-positive advanced breast cancer who had received T-DM1 therapy in the second-line setting and beyond.This retrospective study involved five local centres that provide service for over 80% of the breast cancer population in Hong Kong. The study period was from December 2013 to December 2015. Patients were included if they had recurrent or metastatic histologically confirmed HER2+ breast cancer who had progressed after at least one line of anti-HER2 therapy including trastuzumab. Patients were excluded if they received T-DM1 as first-line treatment for recurrent or metastatic HER2+ breast cancer. Patient charts including biochemical and haematological profiles were reviewed for background information, T-DM1 response, and toxicity data. Adverse events were documented during chemotherapy and 28 days after the last dose of medication.Among 37 patients being included in this study, 28 (75.7%) had two or more lines of anti-HER2 agents and 26 (70.3%) had received two or more lines of palliative chemotherapy. Response assessment revealed that three (8.1%) patients had a complete response, eight (21.6%) a partial response, 11 (29.7%) a stable disease, and 12 (32.4%) a progressive disease; three patients could not be assessed. The median duration of response was 17.3 (95% confidence interval, 8.4-24.8) months. The clinical benefit rate (complete response + partial response + stable disease, ≥12 weeks) was 37.8% (95% confidence interval, 22.2%-53.5%). The median progression-free survival was 6.0 (95% confidence interval, 3.3- 9.8) months and the median overall survival had not been reached by the data cut-off date. Grade 3 or 4 toxicities included thrombocytopaenia (13.5%), raised alanine transaminase (8.1%), anaemia (5.4%), and hypokalaemia (2.7%). No patient died as a result of toxicities.In patients with HER2-positive advanced breast cancer who have been heavily pretreated with anti-HER2 agents and cytotoxic chemotherapy, T-DM1 is well tolerated and provided a meaningful progression-free survival of 6 months and an overall survival that has not been reached. Further studies to identify appropriate patient subgroups are warranted." @default.
• W2783139623 created "2018-01-26" @default.
• W2783139623 creator A5006443491 @default.
• W2783139623 creator A5007089296 @default.
• W2783139623 creator A5008092716 @default.
• W2783139623 creator A5011273870 @default.
• W2783139623 creator A5024002292 @default.
• W2783139623 creator A5035460082 @default.
• W2783139623 creator A5046577935 @default.
• W2783139623 creator A5058144971 @default.
• W2783139623 creator A5058429269 @default.
• W2783139623 creator A5078998472 @default.
• W2783139623 creator A5087585351 @default.
• W2783139623 creator A5088390832 @default.
• W2783139623 date "2018-01-12" @default.
• W2783139623 modified "2023-10-10" @default.
• W2783139623 title "Efficacy and tolerability of trastuzumab emtansine in advanced human epidermal growth factor receptor 2–positive breast cancer" @default.
• W2783139623 doi "https://doi.org/10.12809/hkmj176808" @default.
• W2783139623 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29326401" @default.
• W2783139623 hasPublicationYear "2018" @default.
• W2783139623 type Work @default.
• W2783139623 sameAs 2783139623 @default.
• W2783139623 citedByCount "3" @default.
• W2783139623 countsByYear W27831396232020 @default.
• W2783139623 countsByYear W27831396232021 @default.
• W2783139623 countsByYear W27831396232022 @default.
• W2783139623 crossrefType "journal-article" @default.
• W2783139623 hasAuthorship W2783139623A5006443491 @default.
• W2783139623 hasAuthorship W2783139623A5007089296 @default.
• W2783139623 hasAuthorship W2783139623A5008092716 @default.
• W2783139623 hasAuthorship W2783139623A5011273870 @default.
• W2783139623 hasAuthorship W2783139623A5024002292 @default.
• W2783139623 hasAuthorship W2783139623A5035460082 @default.
• W2783139623 hasAuthorship W2783139623A5046577935 @default.
• W2783139623 hasAuthorship W2783139623A5058144971 @default.
• W2783139623 hasAuthorship W2783139623A5058429269 @default.
• W2783139623 hasAuthorship W2783139623A5078998472 @default.
• W2783139623 hasAuthorship W2783139623A5087585351 @default.
• W2783139623 hasAuthorship W2783139623A5088390832 @default.
• W2783139623 hasBestOaLocation W27831396231 @default.
• W2783139623 hasConcept C121608353 @default.
• W2783139623 hasConcept C126322002 @default.
• W2783139623 hasConcept C143998085 @default.
• W2783139623 hasConcept C197934379 @default.
• W2783139623 hasConcept C2775930923 @default.
• W2783139623 hasConcept C2776694085 @default.
• W2783139623 hasConcept C2777329042 @default.
• W2783139623 hasConcept C2777909004 @default.
• W2783139623 hasConcept C2778087150 @default.
• W2783139623 hasConcept C2778375690 @default.
• W2783139623 hasConcept C2778822529 @default.
• W2783139623 hasConcept C2779786085 @default.
• W2783139623 hasConcept C2779984678 @default.
• W2783139623 hasConcept C2908647359 @default.
• W2783139623 hasConcept C526805850 @default.
• W2783139623 hasConcept C530470458 @default.
• W2783139623 hasConcept C71924100 @default.
• W2783139623 hasConcept C99454951 @default.
• W2783139623 hasConceptScore W2783139623C121608353 @default.
• W2783139623 hasConceptScore W2783139623C126322002 @default.
• W2783139623 hasConceptScore W2783139623C143998085 @default.
• W2783139623 hasConceptScore W2783139623C197934379 @default.
• W2783139623 hasConceptScore W2783139623C2775930923 @default.
• W2783139623 hasConceptScore W2783139623C2776694085 @default.
• W2783139623 hasConceptScore W2783139623C2777329042 @default.
• W2783139623 hasConceptScore W2783139623C2777909004 @default.
• W2783139623 hasConceptScore W2783139623C2778087150 @default.
• W2783139623 hasConceptScore W2783139623C2778375690 @default.
• W2783139623 hasConceptScore W2783139623C2778822529 @default.
• W2783139623 hasConceptScore W2783139623C2779786085 @default.
• W2783139623 hasConceptScore W2783139623C2779984678 @default.
• W2783139623 hasConceptScore W2783139623C2908647359 @default.
• W2783139623 hasConceptScore W2783139623C526805850 @default.
• W2783139623 hasConceptScore W2783139623C530470458 @default.
• W2783139623 hasConceptScore W2783139623C71924100 @default.
• W2783139623 hasConceptScore W2783139623C99454951 @default.
• W2783139623 hasLocation W27831396231 @default.
• W2783139623 hasLocation W27831396232 @default.
• W2783139623 hasLocation W27831396233 @default.
• W2783139623 hasOpenAccess W2783139623 @default.
• W2783139623 hasPrimaryLocation W27831396231 @default.
• W2783139623 hasRelatedWork W2034727235 @default.
• W2783139623 hasRelatedWork W2083781956 @default.
• W2783139623 hasRelatedWork W2090403447 @default.
• W2783139623 hasRelatedWork W2143324226 @default.
• W2783139623 hasRelatedWork W2402043385 @default.
• W2783139623 hasRelatedWork W2783139623 @default.
• W2783139623 hasRelatedWork W2944015322 @default.
• W2783139623 hasRelatedWork W3212173559 @default.
• W2783139623 hasRelatedWork W4221053062 @default.
• W2783139623 hasRelatedWork W4236572708 @default.
• W2783139623 isParatext "false" @default.
• W2783139623 isRetracted "false" @default.
• W2783139623 magId "2783139623" @default.
• W2783139623 workType "article" @default.